Atlas Trials

Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

Clinical trial NCT06532058 · UNKNOWN

Trial details

NCT number
NCT06532058
Sponsor
Changzhou Qianhong Bio-pharma Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)
Start date
2023-08-10
Primary completion
2025-02-10
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.